GlassScriptPhysician profile
Michelle A Beutz
NPI 1275509689
$1,771.26
in general payments reported to CMS, 2019-2025
25 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $141 · 2021: $107 · 2022: $225 · 2023: $171 · 2024: $287 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $247.02 | 2019-2023 | Uptravi |
| Merck Sharp & Dohme LLC | $224.36 | 2020-2025 | Winrevair |
| United Therapeutics Corporation | $208.18 | 2019-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $194.82 | 2019-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $142.58 | 2023-2024 | Inspire |
| Ethicon US, LLC | $140.44 | 2019 | |
| Gilead Sciences, INC. | $77.05 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $51.78 | 2020-2023 | Symbicort |
| Glaxosmithkline, LLC. | $45.52 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $39.61 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.45 | 2019-2025 | Dupixent |
| Zoll Respicardia, INC. | $36.62 | 2023-2025 | Remede System |
| Harmony Biosciences LLC | $33.78 | 2021 | |
| Axsome Therapeutics, INC. | $31.81 | 2024 | Sunosi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.94 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $23.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.92 | 2022 | |
| Amgen INC. | $18.96 | 2024 | Tezspire |
| Mylan Specialty L.P. | $18.86 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.77 | 2024 | Nuzyra |
| Genentech USA, INC. | $17.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.57 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.95 | 2019 | |
| Circassia INC. | $13.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Beutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.